Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant
Key Points
Donor-derived T cells with native specificity for multiple myeloid leukemia antigens can be expanded ex vivo.
Infusion of mLSTs after HCT is well tolerated and produces antileukemia effects.


